Rates and determinants of virologie and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 5, 2008, Pages 492-498

  Touloumi, Giota ^a   Pantazis, Nikos ^a   Stirnadel, Heide A ^b   Walker, A Sarah ^c   Boufassa, Faroudy ^d   Vanhems, Philippe ^e   Porter, Kholoud ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b GLAXOSMITHKLINE   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIVERSITÉ DE LYON   (France)

Author keywords

HAART resumption; HIV infection; Immunological response; Prognostic factors; Treatment interruption; Virologie response

Indexed keywords

RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME RECONSTITUTION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; SEROCONVERSION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; VIROLOGY; VIRUS LOAD; ADOLESCENT; DRUG ADMINISTRATION; IMMUNOLOGY;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; YOUNG ADULT;

EID: 62749157605     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318186ead2     Document Type: Article

References (35)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997; 337:725-733.
3. Hogg RS, Havlir D, Miller V, et al. To stop or not to stop: that is the question, but what is the answer? AIDS. 2002;16:787-789.
4. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423-1430.
5. 3. J Infect Dis. 2005;192:1787-1793.
6. Giuntini R, Marttinelli C, Ambu S, et al. Prolonged treatment interruption in chronic HIV infection: a new strategy? AIDS. 2005;19:209-215.
7. Boschi A, Tinelli C, Ortolani P, et al. CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy. AIDS. 2004;18:2381-2389.
8. Garcia F, Plana M, Ortiz GM, et al. The virologie and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS. 2001;15:F29-F40.
9. Lawrence J, Mayers DL, Hullsiek KH, et al, for the 064 Study Team of the Terry Beim Community Programs for Clinical Research on AIDS. Structured treatment interruption in patients with multi-resistant human immunodeficiency virus. N Engl J Med. 2003;349:837-846.
10. El-Sadr W, Lundgren JD, Neaton J, et al. for the SMART Study Group. CD4- count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2282-2296.
11. d'Arminio Monforte A, Cozzi-Lepri A, Phillips A, et al. Interruption of highly active antiretroviral therapy in HIV clinical practice. J Acquir Immune Defic Syndr. 2005;38:407-416.
12. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001;15:185-194.
13. Sanchez R, Portilla J, Gimeno A, et al. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment. J Infect. 2007;54:159-166.
14. Gardiello PG, Hassink E, Ananworanich J, et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis. 2005;40:594-600.
15. Poulton MB, Sabin CA, Fisher M. Immunological changes during treatment interruptions: risk factors and clinical sequelae. AIDS. 2003;17:126-128.
16. Maggiolo F, Ripamonti D, Gregis G, et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS. 2004;18:439-446.
17. Touloumi G, Pantazis N, Antoniou A, et al, on behalf of the CASCADE Collaboration. Highly active antiretroviral therapy interruption: predictors and virologie and immunological consequences. J Acquir Immune Defic Syndr. 2006;42:554-561.
18. Gianotti N, Soria A, Galli L, et al. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy. J Med Virol. 2004;72:181-186.
19. Jaafar A, Massip P, Sandres-Saune K, et al. HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4- T lymphocyte count. J Med Virol. 2004;74:8-15.
20. CASCADE Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med. 2000;1:224-231.
21. Skiest DJ, Morrow P, Allen B, et al. It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts >250 cells/μl. J Aquir Immune Defic Syndr. 2004;37:1351-1357.
22. Tarwater PM, Parish M, Gallant JE. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis. 2003;37:1541-1548.
23. Boschi A, Tinelli C, Ortolani P, et al. Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection. J Antimicrob Chemother. 2006;57:520-526.
24. Mata RC, Viciana P, de Alarcon A, et al. Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologie, and immunologic consequences. AIDS Patient Care STDS. 2005;19:550-562.
25. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med. 1998;4:208-214.
26. El-Sadr W, SMART Study Group. Re-initiation of ART in the CD4-guided ART interruption group in the SMART Study lowers risk of opportunistic diseases or death. Presented at: 15th Conference on Retrovirus and Opportunistic Infections, February 3-6, 2008; Boston, MA. Abstract 36.
27. Cohn D, for the SMART Study Group. Severity and types of clinical events by proximal CD4 cell counts in the SMART study. Presented at: XVI International AIDS Conference, August 13-18, 2006; Toronto, Canada. [THPE0047].
28. Boom J, Kosters E, Duncombe C, et al. Feritin levels during structured treatment interruption of highly active antiretroviral therapy. HW Med. 2007;8:388-395.
29. Arjona MM, Perez-Cano R, Garcia-Juarez R, et al. Structured intermittent interruption of chronic HIV infection treatment with highly active antiretroviral therapy: effects on leptin and TNF-alpha. AIDS Res Hum Retroviruses. 2006;22:307-314.
30. Wainberg MA, Clotet B. Immunologic response to protease inhibitorbased highly active antiretroviral therapy: a review. AIDS Patient Care STDS. 2007;21:609-620.
31. + cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologie suppression. Clinl Infect Dis. 2007;44:441-446.
32. Florence E, Lundgren J, Dreezen C, et al, for the EuroSIDA Study Group. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIVMed. 2003;4:255-262.
33. Ribeiro RM, Mohri H, Ho DD, et al. In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4- but not CD8+ T cells depleted? Proc Natl Acad Sci USA. 2002;99:15572-15577.
34. Le Moing V, Thiebaut R, Chene G, et al. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. HIV Med. 2007;8:156-163.
35. Gras L, Van Sighem A, Fraser C, et al, and the ATHENA Cohort Study Group. Predictors for changes in CD4 cell count 7 years after starting HAART. Presented at: 13th Conference on Retroviruses and Opportunistic Infections, February 5-8, 2006; Denver, CO. Abstract 530.